Edesa Biotech, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $EDSA in the last 30 days.
See all $EDSA insider activity →Edesa Biotech (EDSA) raised the annual base salaries of its CEO, President, and CFO, effective July 1, 2026. CEO's salary increased from $357,696 to $657,423, President's from $335,340 to $591,681, and CFO's from $300,000 to $525,938. The company did not disclose reasons for the increases.
Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 23, 2026, the Board of Directors (the “Board”) of Edesa Biotech, Inc. (the “Company”), upon the recommendation o
Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 15, 2026, Edesa Biotech, Inc. (the “Company”) reported that the U.S. Food and Drug Administration (“FDA”) has cleared the Company's Investigational New Drug (“IND”) application for its Phase 2 clinical study of EB06 in vitiligo, enabling the Co
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning EDSA (Edesa Biotech, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent EDSA coverage spans corporate actions, regulation and market movers.
Compensation increase adds to operating expenses but unlikely to move the stock materially.
Compensation increase may raise cost base but no immediate operational impact.
The clearance removes a regulatory hurdle and may lift the stock on expectations of future data.
The clearance removes a regulatory hurdle, allowing patient recruitment in the U.S. and setting a timeline for topline data in Q4 2027.
Capital raise provides funding runway, likely supportive for price.
AlphAI scores every news story that mentions EDSA with an AI model for sentiment and relevance, and aggregates insider trades from Edesa Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Edesa Biotech (EDSA) raised the annual base salaries of its CEO, President, and CFO, effective July 1, 2026. CEO's salary increased from $357,696 to $657,423, President's from $335,340 to $591,681, and CFO's from $300,000 to $525,938. The company did not disclose reasons for the increases.
1 min readEdesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 23, 2026, the Board of Directors (the “Board”) of Edesa Biotech, Inc. (the “Company”), upon the recommendation o
1 min readEdesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On October 15, 2026, Edesa Biotech, Inc. (the “Company”) reported that the U.S. Food and Drug Administration (“FDA”) has cleared the Company's Investigational New Drug (“IND”) application for its Phase 2 clinical study of EB06 in vitiligo, enabling the Co
1 min readEdesa Biotech (EDSA) received FDA clearance to expand its Phase 2 vitiligo study to U.S. sites, with enrollment expected next quarter. Topline data is anticipated for Q4 2027. The study evaluates EB06, a monoclonal antibody targeting CXCL10, in 80 adults with moderate-to-severe vitiligo. Edesa aims to report results in late 2027, marking a key milestone for its vitiligo program.
2 min readSummit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
3 min readEdesa Biotech (EDSA) agreed with Guggenheim Securities to offer 3.87M shares at $5.50 each, plus warrants, and 675K pre-funded warrants at $5.4999, with a 30-day option for 681,825 more. The $23.1M offering, expected to close by Aug 21, 2026, will fund corporate and R&D needs, according to the company.
1 min readEdesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Edesa Biotech Announces Proposed Public Offering TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammat
2 min readEdesa Biotech (EDSA) priced a $25M public offering, including 3.87M common shares, warrants, and pre-funded warrants. The combined offering price is $5.50 per share and warrant. Guggenheim Securities leads the underwriting. The offering is expected to close on August 21, 2026.
1 min readEdesa Biotech (NASDAQ:EDSA) shares dropped 15.2% after hours Wednesday after launching a public offering of common shares and warrants. The company plans to use proceeds for corporate purposes, including R&D and manufacturing. The offering is subject to market conditions and has no guaranteed completion.
3 min readTenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.
6 min read
